Effect of Quercetin on Prophylaxis and Treatment of COVID-19
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04377789|
Recruitment Status : Completed
First Posted : May 6, 2020
Last Update Posted : February 18, 2021
|Condition or disease||Intervention/treatment||Phase|
|COVID-19||Dietary Supplement: Quercetin Prophylaxis Dietary Supplement: Quercetin Treatment||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||447 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Possible Effect of Quercetin on Prophylaxis and Treatment of COVID-19|
|Actual Study Start Date :||March 20, 2020|
|Actual Primary Completion Date :||July 31, 2020|
|Actual Study Completion Date :||August 31, 2020|
No Intervention: non-quercetin group
Participants, who accept to enroll the study without having quercetin prophylaxis and who do not have a history of COVID-19, will be in this group.
Active Comparator: quercetin prophylaxis group
Participants, who takes a daily dose of 500mg quercetin and who not have a history of COVID-19, will be in this group.
Dietary Supplement: Quercetin Prophylaxis
a daily dose of quercetin (500mg) will be taken by non-COVID-19 intervention group 1
Active Comparator: quercetin treatment group
Participants, who takes a daily dose of 1000mg quercetin and who are proven cases for COVID-19, will be in this group.
Dietary Supplement: Quercetin Treatment
a daily dose of quercetin (1000mg) will be taken by proven COVID-19 cases intervention group 2
- Prevalence of COVID-19 calculated using a questionnaire [ Time Frame: 3 months ]Prevalence of COVID-19 in prophylaxis and sham group will be calculated using a questionnaire including hospital records
- Standardized Mortality rate [ Time Frame: 3 months ]Mortality rate will be compared between two groups
- Morbidity rate [ Time Frame: 3 months ]Morbidity rates besides recovery rates from COVID-19 will be documented
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04377789
|Kanuni Sultan Suleyman Training and Research Hospital|
|Istanbul, Turkey, 34303|